Why McKesson Is Poised to Keep Rallying

Brian D. Pacampara, The Motley Fool
Updated

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical distributor McKesson has earned a coveted five-star ranking.

With that in mind, let's take a closer look at McKesson and see what CAPS investors are saying about the stock right now.

McKessonfacts

Headquarters (Founded)

San Francisco (1833)

Market Cap

$24.5 billion

Industry

Health-care distributors

Trailing-12-Month Revenue

$123.2 billion

Management

Chairman/CEO John Hammergren
CFO Jeffrey Campbell

Return on Equity (Average, Past 3 Years)

18.8%

Cash/Debt

$2.8 billion / $3.6 billion

Dividend Yield

0.8%

Competitors

AmerisourceBergen
Cardinal Health
Owens & Minor


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 619 members who have rated McKesson believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, brenoboyle, touched on a few of the tailwinds working in McKesson's favor: "Increasing coverage for prescription drug benefits, very shareholder friendly consistent repurchases, patent cliff for pharma will led to more generic prescription drug coverage for which [McKesson] has higher margins."

If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its five-star rating, McKesson may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why McKesson Is Poised to Keep Rallying originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement